Health information technology and digital innovation for national learning health and care systems.


Journal

The Lancet. Digital health
ISSN: 2589-7500
Titre abrégé: Lancet Digit Health
Pays: England
ID NLM: 101751302

Informations de publication

Date de publication:
06 2021
Historique:
received: 24 04 2020
revised: 24 07 2020
accepted: 04 01 2021
pubmed: 11 5 2021
medline: 8 6 2021
entrez: 10 5 2021
Statut: ppublish

Résumé

Health information technology can support the development of national learning health and care systems, which can be defined as health and care systems that continuously use data-enabled infrastructure to support policy and planning, public health, and personalisation of care. The COVID-19 pandemic has offered an opportunity to assess how well equipped the UK is to leverage health information technology and apply the principles of a national learning health and care system in response to a major public health shock. With the experience acquired during the pandemic, each country within the UK should now re-evaluate their digital health and care strategies. After leaving the EU, UK countries now need to decide to what extent they wish to engage with European efforts to promote interoperability between electronic health records. Major priorities for strengthening health information technology in the UK include achieving the optimal balance between top-down and bottom-up implementation, improving usability and interoperability, developing capacity for handling, processing, and analysing data, addressing privacy and security concerns, and encouraging digital inclusivity. Current and future opportunities include integrating electronic health records across health and care providers, investing in health data science research, generating real-world data, developing artificial intelligence and robotics, and facilitating public-private partnerships. Many ethical challenges and unintended consequences of implementation of health information technology exist. To address these, there is a need to develop regulatory frameworks for the development, management, and procurement of artificial intelligence and health information technology systems, create public-private partnerships, and ethically and safely apply artificial intelligence in the National Health Service.

Identifiants

pubmed: 33967002
pii: S2589-7500(21)00005-4
doi: 10.1016/S2589-7500(21)00005-4
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

e383-e396

Subventions

Organisme : British Heart Foundation
ID : CH/12/3/29609
Pays : United Kingdom

Informations de copyright

Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license. Published by Elsevier Ltd.. All rights reserved.

Auteurs

Aziz Sheikh (A)

Usher Institute, College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, UK. Electronic address: aziz.sheikh@ed.ac.uk.

Michael Anderson (M)

Department of Health Policy, London School of Economics and Political Science, London, UK.

Sarah Albala (S)

UCL Institute for Innovation and Public Purpose, University College London, London, UK.

Barbara Casadei (B)

Radcliffe Department of Medicine, BHF Centre for Research Excellence, NIHR Biomedical Research Centre, John Radcliffe Hospital, University of Oxford, Oxford, UK.

Bryony Dean Franklin (BD)

UCL School of Pharmacy, University College London, London, UK; NIHR Imperial Patient Safety Translational Research Centre, Imperial College Healthcare NHS Trust, London, UK.

Mike Richards (M)

Department of Health Policy, London School of Economics and Political Science, London, UK; The Health Foundation, London, UK.

David Taylor (D)

UCL School of Pharmacy, University College London, London, UK.

Holly Tibble (H)

Usher Institute, College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, UK.

Elias Mossialos (E)

Department of Health Policy, London School of Economics and Political Science, London, UK; Institute of Global Health Innovation, Imperial College London, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH